Holen Sie sich die Stockscreener-App
2.56
4.92%
0.12
Vorhandelsmarkt:
2.66
0.10
+3.91%
Schlusskurs vom Vortag:
$2.44
Offen:
$2.51
24-Stunden-Volumen:
416.08K
Relative Volume:
0.06
Marktkapitalisierung:
$8.36M
Einnahmen:
$960.60K
Nettoeinkommen (Verlust:
$-7.10M
KGV:
-0.3386
EPS:
-7.56
Netto-Cashflow:
$-8.00M
1W Leistung:
-14.09%
1M Leistung:
+101.57%
6M Leistung:
+11.30%
1J Leistung:
-17.15%
1-Tages-Spanne:
$2.36
$2.585
1-Wochen-Bereich:
$2.32
$3.75
52-Wochen-Spanne:
$1.09
$5.40
Soligenix Inc Stock (SNGX) Company Profile
Firmenname
Soligenix Inc
Sektor
Branche
Telefon
609-538-8200
Adresse
29 EMMONS DRIVE, PRINCETON
Vergleichen Sie SNGX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SNGX
Soligenix Inc
|
2.56 | 7.97M | 960.60K | -7.10M | -8.00M | -7.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.77 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.93 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
637.56 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.10 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Soligenix Inc Stock (SNGX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-07-28 | Herabstufung | Dawson James | Buy → Neutral |
| 2018-01-31 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2017-08-14 | Bestätigt | Maxim Group | Buy |
| 2017-07-17 | Eingeleitet | H.C. Wainwright | Buy |
Soligenix Inc Aktie (SNGX) Neueste Nachrichten
Is Soligenix Inc. a stock for growth or value investorsFast Explosive Return Stocks - newsyoung.net
Alliance Global Partners Raises Soligenix Price Target Amid Clinical Advancements - citybuzz -
Alliance Global Partners Maintains Buy Rating, Increases Price Target as Soligenix (NASDAQ: SNGX) Advances Proprietary Clinical Programs - The Globe and Mail
How do insiders feel about Soligenix Inc.Free Investment Newsletter - classian.co.kr
Unraveling Soligenix’s Sharp Drop: Was It a Sell-Off or a Buying Opportunity? - AInvest
NetworkNewsAudio Announces Audio Press Release (APR) on Promising First-Line Therapy for Rare Skin Cancer - GlobeNewswire
Soligenix (NASDAQ: SNGX) Featured in NNW Editorial on Rare Disease Innovation - The Globe and Mail
Soligenix Inc. (NASDAQ: SNGX) Proprietary Platform Aims to Meet Growing Need for Effective CTCL Therapy - GlobeNewswire
Breakthrough CTCL Cancer Treatment: Soligenix Advances US-Made HyBryte Platform as Aging Population Surges - Stock Titan
Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators - The Malaysian Reserve
Canadian Investment Regulatory Organization Trading HaltPCLO - The Globe and Mail
Soligenix Inc expected to post a loss of 92 cents a shareEarnings Preview - TradingView
Soligenix Inc. Featured in NetworkNewsWire Editorial Highlighting Advances in Rare Disease Treatments - Quiver Quantitative
Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space - GlobeNewswire
Breakthrough: Soligenix's Rare Disease Treatment HyBryte Achieves Major Manufacturing Milestone for CTCL Therapy - Stock Titan
Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic Areas - The Malaysian Reserve
Momentum Screeners Rank Soligenix Inc. in Top 5 TodayShort Term Trading Opportunity Watch Sees Shift - metal.it
Soligenix Stock Shoots Up: Time to Dive In? - StocksToTrade
Soligenix’s Phase 3 Study on HyBryte for CTCL: Key Insights for Investors - MSN
Soligenix’s Stock Soars: What’s Fueling the Boom? - timothysykes.com
Is Soligenix Inc. a good long term investmentExceptional market positioning - Jammu Links News
How volatile is Soligenix Inc. stock compared to the marketFree Wealth Planning Blueprint - Jammu Links News
What catalysts could drive Soligenix Inc. stock higher in 2025Grow your wealth steadily and securely - Jammu Links News
What markets is FATBB expanding into Is Soligenix Inc. stock a good long term investment optionTrack high-yield stocks before they peak - Jammu Links News
How does Soligenix Inc. generate profit in a changing economyUnlock exclusive stock market forecasts - Jammu Links News
What institutional investors are buying Soligenix Inc. stockUnlock exclusive stock market forecasts - Jammu Links News
What is Soligenix Inc. company’s growth strategyMaster stock selection with insider knowledge - Jammu Links News
What is the dividend policy of Soligenix Inc. stockCapitalize on market momentum for big wins - Jammu Links News
What makes Soligenix Inc. stock price move sharplySky-high profits - Jammu Links News
Is Soligenix Inc. a growth stock or a value stockFree Capital Allocation Plans - Jammu Links News
What is the risk reward ratio of investing in Soligenix Inc. stockDiscover high-return stocks for your portfolio - Jammu Links News
How strong is Soligenix Inc. company’s balance sheetFree Investment Risk Control - Jammu Links News
What are the latest earnings results for Soligenix Inc.Outstanding yields - Jammu Links News
Should I hold or sell Soligenix Inc. stock in 2025AI Powered Report For Fast Growth - jammulinksnews.com
Soligenix Completes Phase 2a Study for SGX945 - The Globe and Mail
Soligenix Completes Promising Study on Dusquetide for Behcet’s Disease - TipRanks
How does Soligenix Inc. compare to its industry peersEarnings Report Watchlist Backed By Experts - jammulinksnews.com
Soligenix Stock Skyrockets: Should You Invest? - timothysykes.com
Why Did Soligenix Plunge 12.97% Despite Positive Trial Results? - AInvest
Soligenix’s $1.17B Volume Surge Propels 134% Rally, Ranked 108th in Market Activity - AInvest
Soligenix Reports Positive Phase 2a Data in Behçet’s Disease - Dermatology Times
SNGX.O (Soligenix) Surges 144%: A Deep Dive into the Drivers Behind the Intraday Move - AInvest
SNGX: Encouraging Results from Phase 2a Study of SGX945 in Behcet’s Disease… - Zacks Small Cap Research
This Stock Soared after Successful Treatment of Rare Disease - FXLeaders
Soligenix (NASDAQ: SNGX) Achieves Biological Efficacy in Phase 2a SGX945 Study for Behçet’s Disease - Barchart.com
Soligenix shares surge 106.40% intraday after completing Phase 2a proof of concept study for SGX945 in Behcet's Disease. - AInvest
Soligenix Stock Soars: Is A Rebound Imminent? - StocksToTrade
Why Is Soligenix Stock (SNGX) Up 50% Today? - TipRanks
Soligenix Stock Skyrockets: What Comes Next? - timothysykes.com
Soligenix Drug Matches FDA-Approved Amgen Therapy In Rare Disease Trial - Yahoo Finance
Soligenix reports positive results from SGX945 Behçet’s trial By Investing.com - Investing.com Nigeria
Finanzdaten der Soligenix Inc-Aktie (SNGX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.91%
3.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):